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(Not) measuring in the dark
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Do we really care about tuberculosis (TB) mortality? When one looks at global targets for 
disease control, it certainly seems that the answer is yes. Ambitious global targets were set 
to reduce TB deaths by 50% by 2015, and the World Health Organization post-2015 strategy 
includes a target of a 95%reduction in TB mortality by 2035.1 However, the opposite 
conclusion might be reached if gauged by the lack of robustness in global measurement of 
TB mortality.
In 2013, only 124 of 195 countries had vital registration systems that were deemed to be of 
sufficient completeness and quality to be usable for direct measurement of TB mortality. In 
addition, India and Viet Nam had conducted mortality surveys, yielding 126 countries with 
adequate measures of TB mortality. However, only 36% of estimated TB deaths occur in 
these 126 countries, and none of the countries are in sub-Saharan Africa, where TB-related 
death is most common.2 Further complicating our ability to determine the number of deaths 
attributable to TB is that deaths due to TB in people with human immunodeficiency virus 
(HIV) are recorded as HIV deaths in ICD-10. Therefore, even when vital registration or 
survey data do exist, estimates of TB mortality in people with HIV are limited. Taken 
together, it is clear that we lack accurate estimates of TB deaths worldwide.
The study by Omar et al. in this issue of the Journal suggests that mortality surveillance may 
not only be important, given the high burden of undiagnosed TB, it may also be feasible 
with minimally invasive methods.3 Post-mortem specimen collections were conducted 
within a median of 5 days by a trained nurse who obtained multiple respiratory samples 
through lung core biopsy and modified bronchoalveolar lavage (BAL). Overall, 32% of 
decedents had evidence of TB from at least one diagnostic test.
That TB was an exceptionally common cause of death in this population is not a new 
finding. A recent meta-analysis by Gupta et al. reported that 40% of facility-based deaths in 
people with HIV were caused by TB.4 What is novel is the use of a minimally invasive 
procedure conducted by a nurse to ascertain cause of death. This approach and finding 
should encourage the further development of feasible approaches for accurate mortality 
measurement in high-burden TB countries, including the many countries where vital 
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registration and survey data are lacking. Additional studies are needed aimed at identifying a 
combination of specimens that can be collected through minimally invasive methods which 
will have high sensitivity and specificity for diagnosing TB.
Death is a common, unifying condition that crosses disease boundaries. As such, it is not 
just TB for which mortality measurement is important: malaria and HIV programs also seek 
to reduce mortality, and maternal and child health programs target mortality impact as a key 
outcome measure. Thus, working across programs, a valid and minimally invasive set of 
specimens and tests could aim not only to accurately diagnose TB, but also to detect malaria, 
common opportunistic infections, and other priority health conditions.
TB continues to have an unacceptable impact globally, with an estimated 1.5 million deaths 
per year, or 150–200 deaths per hour, from a treatable, preventable disease. Currently, TB 
incidence is falling at a rate of approximately 1% per year globally.2 The rate of decline is 
far slower than the nearly 20% per year required to reach global elimination targets by 2050. 
Based on modeling data, we could substantially accelerate progress by implementing the 
right combination of TB program measures, with an even more immediate impact on 
mortality than on incidence.5 Until tools are developed to measure this progress accurately, 
developing and demonstrating successful models for achieving these goals will be very 
difficult. We do care greatly about reducing TB mortality. Now is the time to improve 
surveillance so that high-impact strategies can be identified and more lives saved.
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